BioMarin Pharmaceutical

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and BioMarin strive to quickly develop important therapies for them.

The Company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® for mucopolysaccharidosis VI; Aldurazyme® for mucopolysaccharidosis I; and Kuvan® Tablets, for phenylketonuria.

Type
Public
HQ
San Rafael, US
Founded
1997
Size (employees)
2,293 (est)+7%
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, US

BioMarin Pharmaceutical Office Locations

BioMarin Pharmaceutical has offices in San Rafael, Novato, Kronberg im Taunus, Cork and in 29 other locations
San Rafael, US (HQ)
770 Lindaro St
Hong Kong, HK
Mass Mutual Tower 38 Gloucester Rd
Mocoa, CO
96 Cra. 9
London, GB
10 Bloomsbury Way
Leiden, NL
Biopartner Gebouw 1 21 J.H. Oortweg
Dublin, IE
Saint James House Adelaide Rd
Show all (34)

BioMarin Pharmaceutical Data and Metrics

BioMarin Pharmaceutical Financial Metrics

BioMarin Pharmaceutical's revenue was reported to be $303.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

303.7 m

Gross profit (Q1, 2017)

253.7 m

Gross profit margin (Q1, 2017), %

84%

Net income (Q1, 2017)

(16.3 m)

EBIT (Q1, 2017)

(20.2 m)

Market capitalization (21-Jul-2017)

15.2 b

Cash (31-Mar-2017)

348.2 m
BioMarin Pharmaceutical's current market capitalization is $15.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

548.5 m751 m889.9 m1.1 b

Revenue growth, %

37%18%26%

Cost of goods sold

95.7 m129.8 m152 m209.6 m

Gross profit

452.7 m621.3 m737.9 m907.2 m

Gross profit Margin, %

83%83%83%81%

R&D expense

661.9 b

General and administrative expense

476.6 b

Operating expense total

608.8 m843.9 m1 b1.9 b

EBIT

(156 m)(92.9 m)(110.7 m)(803.4 m)

EBIT margin, %

(28%)(12%)(12%)(72%)

Interest expense

10.4 m36.6 m38.2 m39.5 m

Interest income

3.1 m5.9 m4.5 m7.5 b

Pre tax profit

(176.5 m)(124.9 m)(154.7 m)(831.1 m)

Income tax expense

(150 k)9.1 m17.1 m(200.8 m)

Net Income

(176.4 m)(134 m)(171.8 m)(630.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

191.8 m176.8 m203.3 m250.5 m208.9 m236.7 m300 b279.9 m303.7 m

Cost of goods sold

31.2 m29.9 m32.8 m39.9 m36.7 m43.1 m51.6 b50.7 m50 m

Gross profit

160.6 m146.9 m170.5 m210.6 m172.2 m193.6 m248.4 b229.2 m253.7 m

Gross profit Margin, %

84%83%84%84%82%82%83%82%84%

R&D expense

107.7 m125.7 m142.1 m157.9 m158.7 m158.8 m167 b160.8 m145 m

General and administrative expense

68.1 m74.6 m92.8 m101.5 m94 m105.3 m110 b118.8 m120 m

Operating expense total

175.8 m200.3 m234.9 m259.4 m252.8 m264.1 m277 b279.6 m265 m

EBIT

(18.9 m)11.2 m(65.9 m)(64.2 m)(81.9 m)(80.9 m)(573 b)(60.1 m)(20.2 m)

EBIT margin, %

(10%)6%(32%)(26%)(39%)(34%)(191%)(21%)(7%)

Interest expense

(9.2 m)(9.1 m)(9.5 m)(10 m)(9.4 m)(9.8 m)(9.9 b)(10 m)(10.1 m)

Interest income

1.7 m1.4 m683 k1 m1.3 m1.6 m1.4 b1.6 m3.1 m

Pre tax profit

(27.7 m)3.2 m(74.7 m)(82.5 m)(90.4 m)(89.1 m)(583 b)(66.8 m)(24.3 m)

Income tax expense

5.8 m(4.2 m)(7.2 m)(555 k)483 k(24 m)

Net Income

(33.5 m)7.4 m(67.5 m)(82 m)(90.9 m)(85.1 m)(424 b)(42.8 m)(16.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

568.8 m875.5 m397 m408.3 m

Accounts Receivable

117.8 m144.5 m165 m215.3 m

Inventories

162.6 m199.5 m271.7 m355.1 m

Current Assets

1.1 b1.4 b1.1 b1.4 b

PP&E

319.3 m523.5 m704.2 m798.8 m

Goodwill

54.3 m54.3 m197 m197 m

Total Assets

2.2 b2.5 b3.7 b4 b

Accounts Payable

370.5 m

Current Liabilities

183.3 m235.7 m445.5 m439.3 m

Total Liabilities

1.3 b

Additional Paid-in Capital

2.1 b2.4 b3.4 b4.3 b

Retained Earnings

(715.8 m)(849.8 m)(1 b)(1.5 b)

Total Equity

1.3 b1.5 b2.4 b2.8 b

Financial Leverage

1.7 x1.6 x1.6 x1.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

584.7 m398 m900.6 m440.7 m376.3 m270.5 m306 m707.3 m348.2 m

Accounts Receivable

122.3 m121.4 m175.7 m186.1 m148.9 m180.8 m214.2 m215.9 m230.3 m

Inventories

193.5 m204.4 m222.8 m237.5 m262.1 m297 m326.6 m347.4 m384.1 m

Current Assets

1.2 b1.1 b1.5 b1.2 b1.2 b992.8 m1.1 b1.7 b1.4 b

PP&E

469.9 m486.7 m538.1 m568.1 m604.5 m716.9 m724.5 m729.8 m824 m

Goodwill

54.3 m54.3 m202.4 m202.4 m202.4 m197 m197 m197 m197 m

Total Assets

2.3 b2.4 b3.7 b3.6 b3.6 b3.7 b3.1 b3.8 b3.9 b

Accounts Payable

166.7 m206.6 m230.2 m256.3 m296.2 m290.6 m292.3 m306.1 m272.4 m

Current Liabilities

166.7 m206.6 m305.5 m347.7 m390.5 m388 m364.6 m377.3 m340.2 m

Additional Paid-in Capital

2.2 b2.3 b3.3 b3.3 b3.4 b3.4 b3.5 b4.2 b4.3 b

Retained Earnings

(787.4 m)(780 m)(917.3 m)(999.3 m)(1.1 b)(1.1 b)(1.5 b)(1.6 b)(1.5 b)

Total Equity

1.5 b1.5 b2.4 b2.3 b2.3 b1.9 b2.6 b2.8 b

Financial Leverage

1.6 x1.6 x1.5 x1.6 x1.6 x1.6 x1.5 x1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(176.4 m)(134 m)(171.8 m)(630.2 m)

Depreciation and Amortization

47.3 m56.7 m47.2 m96.9 m

Accounts Receivable

(8.8 m)(27 m)(16 m)(51.5 m)

Inventories

(34 m)(37 m)(51 m)(64.5 m)

Cash From Operating Activities

(59.6 m)(73.5 m)(221.7 m)(227.8 m)

Purchases of PP&E

(65.1 m)(118.8 m)(227.7 m)(148.4 m)

Cash From Investing Activities

(298.8 m)194.6 m(1.2 b)(484 m)

Cash From Financing Activities

746.7 m185.7 m927.9 m727.1 m

Income Taxes Paid

14.9 m35 m16.1 m95.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(33.5 m)7.4 m(67.5 m)(82 m)(90.9 m)(85.1 m)(424 b)(42.8 m)(16.3 m)

Accounts Receivable

122.3 m121.4 m175.7 m186.1 m148.9 m180.8 m214.2 m215.9 m230.3 m

Inventories

193.5 m204.4 m222.8 m237.5 m262.1 m297 m326.6 m347.4 m384.1 m
USDY, 2017

Revenue/Employee

132.5 k

Financial Leverage

1.4 x

BioMarin Pharmaceutical Operating Metrics

BioMarin Pharmaceutical's Patent Applications was reported to be 426 in FY, 2016
FY, 2016

Phase 1/2

2

Phase III Trials

2

Patents Issued

1.17 k

Patent Applications

426

BioMarin Pharmaceutical Market Value History

BioMarin Pharmaceutical Revenue Breakdown

BioMarin Pharmaceutical Job Categories

BioMarin Pharmaceutical Median Salaries

Source: 52 public H-1B filings from BioMarin Pharmaceutical

BioMarin Pharmaceutical News and Updates

BioMarin Pharmaceutical Company Life and Culture

You may also be interested in